Patient Advocacy Excellence: Optimizing Group Services & Operations

STUDY OVERVIEW

Changing market conditions have made marketplace success contingent on numerous factors that cut across several functional areas of pharmaceutical operations. One functional area that has grown in importance is patient advocacy. As collaborations with patient advocacy groups have become more important for launch and brand success, the activities and roles of biopharma groups serving the patient advocacy sector have evolved.

Best Practices, LLC undertook this research to identify observations, benchmark findings and insights that revolve around effective activities for the biopharma advocacy function. In addition, this study examines the evolving role and responsibilities of the advocacy function in pharma as well as how to communicate the value of advocacy in a pharma organization.

KEY TOPICS

• Advocacy Group Staffing Benchmarks: Key Trends In Resourcing Advocacy Groups
• Advocacy Group Services: Key Trends in Service Levels and Approaches
• Advocacy Roles and Responsibilities: Key Trends in Alliances Management
• Communicating The Value of Advocacy in a Global Bio-Pharma Company

• Does Advocacy differentiate its servcie levels to different internal customers
• Importance rating of factors Advocacy uses to prioritize services/activities for internal stakeholders
• Importance rating of various Advocacy activities and support services
• Rating of various Advocacy activities and support services
• Frequency of interactions with internal groups to learn and share
• Effectiveness rating of different approaches to building ties between Advocacy and internal customers

SAMPLE KEY FINDING

Formalize and Tighten Prioritization Mechanisms: Advocacy prioritizes its service levels based on economic impact, issue importance and stakeholder’s authority. Economic impact has many faces – including impact on costs, revenue or profit. Issue impact can touch a company’s strategy, reputation or marketplace standing. During times of resource constraints, prioritization systems can be better formalized and tightened in order to guide which partners and stakeholders get various services levels.


METHODOLOGY

Participants in this benchmarking research included executive respondents at 11 leading bio-pharmaceutical and healthcare companies. Field interviews and analysis were conducted to produce valuable research insights and findings that augmented an online survey. Research participants included Executive Directors, Medical Executives, Directors and Product Managers. More than 80% of benchmark partners were directors or above – and most worked directly in Advocacy groups or functions.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.